ClinicalTrials.gg

Program

RG002C0106

Its studies are mostly in Glomerulonephritis, IGA, led by Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing).

Furthest: phase 2, since Dec 7, 20254 company-led studies, 3 open or runningNext primary completion: Dec 1, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing)43 open or runningphase 2since Dec 7, 2025Jul 2, 2024Dec 1, 2026phase 1 · NCT07445906

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 2, 2024First study: phase 1 study in Safety IssuesFirst studyNCT06494527 · 50 enrolled · China
  2. Dec 7, 2025Phase 2 study in Glomerulonephritis, IGAPhase 2 reachedNCT07305974 · 30 enrolled · China
  3. Feb 11, 2026Phase 1 study in Glomerulonephritis, IGANCT07445906 · 24 enrolled · China
  4. Oct 10, 2026Phase 1 study in Safety IssuesNCT07902245 · 30 planned · Austria

Ahead

  1. Dec 1, 2026Primary completion: phase 1 study in Glomerulonephritis, IGANCT07445906
  2. Mar 31, 2028Primary completion: phase 1 study in Safety IssuesNCT07902245
  3. Mar 31, 2029Primary completion: phase 2 study in Glomerulonephritis, IGANCT07305974

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07902245Safety Issues · Austria1Not yet recruitingMar 31, 202830
NCT07445906Glomerulonephritis, IGA · China1Active, not recruitingDec 1, 202624
NCT07305974Glomerulonephritis, IGA · China2Active, not recruitingMar 31, 202930
NCT06494527Safety Issues · China1CompletedAug 6, 202650

How it is read

Names in the registry

  • “RG002C0106”, 4 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.